lonigutamab

Lonigutamab is a subcutaneously delivered, humanized IgG1 monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). It binds to a distinct epitope on IGF-1R, resulting in rapid internalization of the receptor and has demonstrated 75-fold greater potency in preclinical binding and functional assays compared to previous agents. Lonigutamab is being developed by Acelyrin for the treatment of thyroid eye disease (TED), also known as Graves' ophthalmopathy, an autoimmune condition characterized by inflammation and expansion of orbital tissues. The drug’s subcutaneous administration allows for longer-term dosing with the potential to improve depth and durability of clinical response while minimizing safety risks associated with intravenous therapies. Clinical trials have shown robust efficacy comparable to IV-administered standard-of-care anti-IGF-1R antibodies, with a favorable safety profile—no reported cases of hearing impairment, hyperglycemia, or menstrual disorders[3][6][7][8].

Other names

Lonigutamab